ABBV STOCK HITS RECORD ALL TIME HIGH

Quote
Stock cant recover and will NEVER see $123 again

AbbVie remains over-reliant on sales of Humira to drive top-line sales - a major red flag as the worldwide patent protection is about to lapse.

Humira will lose patent protection in Europe, and thus in our view, we think we are about to witness peak Humira sales in 2018.

Investors may be over-estimating the productivity of the clinical pipeline, and while there is always a chance AbbVie may come out ahead, we’re not expecting much.

We had been concerned that management executed an accelerated share repurchase scheme earlier this year with the share price trading at all-time highs. It looks like bad timing now.

Our fair value estimate of AbbVie is pegged at $95 per share with a wide fair value range of $71-$119 due in large portion to the uncertainty on how steep the revenue cliff will come from a biosimilar version of Humira.
 




anonymous said:
Stock cant recover and will NEVER see $123 again

AbbVie remains over-reliant on sales of Humira to drive top-line sales - a major red flag as the worldwide patent protection is about to lapse.

Humira will lose patent protection in Europe, and thus in our view, we think we are about to witness peak Humira sales in 2018.

Investors may be over-estimating the productivity of the clinical pipeline, and while there is always a chance AbbVie may come out ahead, we’re not expecting much.

We had been concerned that management executed an accelerated share repurchase scheme earlier this year with the share price trading at all-time highs. It looks like bad timing now.

Our fair value estimate of AbbVie is pegged at $95 per share with a wide fair value range of $71-$119 due in large portion to the uncertainty on how steep the revenue cliff will come from a biosimilar version of Humira.
Click to expand...

Trump bullying pharmaceutical CEOs into backing off price increases so safe to assume no more Humira price increases higher than inflation. Secretary of HHS Azar has also pledged to speed up biosimilar penetration so safe to assume faster than previously anticipated biosimilar erosion. Humira patents expiring in Europe already. Pipeline has suffered significant setbacks and outlook doesn't seem as bright as it once did. AbbVie's SG&A (expenses) is still higher than peer companies (as cited repeatedly by Rick and Bill Chase). All this adds up to massive layoffs and cost cutting to help mitigate an anticipated decline in the ABBV stock price. To exacerbate this, many key employees hired in 2013 hit or will hit their five year vesting period this year so will be looking to leave. I am somewhat cynical so think the target price that Citron has set of $60 per share is closer to reality than the range above ($71-$119).
 




anonymous said:
Trump bullying pharmaceutical CEOs into backing off price increases so safe to assume no more Humira price increases higher than inflation. Secretary of HHS Azar has also pledged to speed up biosimilar penetration so safe to assume faster than previously anticipated biosimilar erosion. Humira patents expiring in Europe already. Pipeline has suffered significant setbacks and outlook doesn't seem as bright as it once did. AbbVie's SG&A (expenses) is still higher than peer companies (as cited repeatedly by Rick and Bill Chase). All this adds up to massive layoffs and cost cutting to help mitigate an anticipated decline in the ABBV stock price. To exacerbate this, many key employees hired in 2013 hit or will hit their five year vesting period this year so will be looking to leave. I am somewhat cynical so think the target price that Citron has set of $60 per share is closer to reality than the range above ($71-$119).
Click to expand...

And add in the fact that ICER is questioning the efficacy, safety profile and price of Orilissa. Uh oh. Drug appears to be heading for prior authorization and secondary status with payers.
 





More bad news for y’all. Express Scripts Is dropping Mavyret in 2019. Next year will be the defining moment for the fall of ABBV and Gonzalez. Looks like Lootsie and Haas will be gone.
 
























anonymous said:
WoW..... and trumpdydumpty isn't doing ABBV any favors.....


looks like path of least resistance is down
Click to expand...

So he got into some fight at schools , how many people in this country have gotten into fights when they were kids at school. He smoked some pot how many people in this country have smoke pot. Because of these reasons that give somone the right to follow this person in present time that is minded their own business, provoke them into a confrontation just so they can shoot them. Oh rightly then.
 








anonymous said:
Trump bullying pharmaceutical CEOs into backing off price increases so safe to assume no more Humira price increases higher than inflation. Secretary of HHS Azar has also pledged to speed up biosimilar penetration so safe to assume faster than previously anticipated biosimilar erosion. Humira patents expiring in Europe already. Pipeline has suffered significant setbacks and outlook doesn't seem as bright as it once did. AbbVie's SG&A (expenses) is still higher than peer companies (as cited repeatedly by Rick and Bill Chase). All this adds up to massive layoffs and cost cutting to help mitigate an anticipated decline in the ABBV stock price. To exacerbate this, many key employees hired in 2013 hit or will hit their five year vesting period this year so will be looking to leave. I am somewhat cynical so think the target price that Citron has set of $60 per share is closer to reality than the range above ($71-$119).
Click to expand...

This post troubles me. Will our leadership act? What will they do? Will the cost-cutting go deep enough to offset the coming cliff in Humira sales? Do our leaders need to be replaced? Do we need changes at the top of R&D and business development? Both seeming to be delivering nothing but disappointment. It is hard to be an optimistic AbbVie employee these days.
 




FDA is working with Boehringer Ingelheim to penetrate Humira Patent. Trying to get Bio Sims launched by end of 2019. Watch Ricks Salary for 2018 be down 40% from 2017.

ABBV $93.66 USD DOWN−0.40 (0.43%)
 




anonymous said:
This post troubles me. Will our leadership act? What will they do? Will the cost-cutting go deep enough to offset the coming cliff in Humira sales? Do our leaders need to be replaced? Do we need changes at the top of R&D and business development? Both seeming to be delivering nothing but disappointment. It is hard to be an optimistic AbbVie employee these days.
Click to expand...

No, Nothing, No,Yes and Yes,
 




News Flash Humira Patent expires in Q418 in Europe. Rick claims only a 20% decline through Q419. and smaller declines thereafter. The real decline will be a whopping 30% off the $6B in sales as there are three biosimilars launching The Stock will NEVER see $123 again and massive RIFs and WARNs are going to be executed in 2020 2021. Better start looking now if you're smart.
 




A tentative settlement in the AndroGel cases is in the works and could be disastrous for AbbVie. Who will pay? Employees will.

That could be the reason for the -5.5% decline over the past month.
 




anonymous said:
News Flash Humira Patent expires in Q418 in Europe. Rick claims only a 20% decline through Q419. and smaller declines thereafter. The real decline will be a whopping 30% off the $6B in sales as there are three biosimilars launching The Stock will NEVER see $123 again and massive RIFs and WARNs are going to be executed in 2020 2021. Better start looking now if you're smart.
Click to expand...
Thats whats driving stock down along with RovaT bad data.
 




anonymous said:
A tentative settlement in the AndroGel cases is in the works and could be disastrous for AbbVie. Who will pay? Employees will.

That could be the reason for the -5.5% decline over the past month.
Click to expand...
I hope Abbvie goes down faster than a Clinton White House intern...or falls faster than Bill Clinton’s pants.
June 29th I quit caring!
 




Don't be silly. AbbVie has far bigger problems, short and long term, than an Androgel settlement. A weak pipeline combined with real medium-range threats to Humira including Trump's plan on drug prices, a ban on rebates, plans to accelerate uptake of biosimilars are only a few. No solution in sight.
 








Top Bottom
Back
Quote